Screener
Sana Biotechnology SANA Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $28,719 | $37,189 |
| Research and development related success payments and contingent consideration | 8,433 | 1,957 |
| General and administrative | 11,462 | 11,484 |
| Total operating expenses | 48,614 | 50,630 |
| Loss from operations | (48,614) | (50,630) |
| Interest income, net | 951 | 992 |
| Other income, net | 453 | 249 |
| Net loss | $(47,210) | $(49,389) |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's total operating expenses?
- Sana Biotechnology (SANA) reported total operating expenses of $48.61M in Q1 2026.
- How has Sana Biotechnology's total operating expenses changed year-over-year?
- Sana Biotechnology's total operating expenses decreased by 4.0% year-over-year, from $50.63M to $48.61M.
- What is the long-term trend for Sana Biotechnology's total operating expenses?
- Over 4 years (2021 to 2025), Sana Biotechnology's total operating expenses has grown at a -9.6% compound annual growth rate (CAGR), from $375.46M to $250.32M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Sana Biotechnology's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude